PT  - JOURNAL ARTICLE
AU  - Leibinger, Anna
AU  - Holliday, Nicole
AU  - Huizinga, Oliver
AU  - von Philipsborn, Peter
TI  - Reach and public health implications of proposed new food marketing regulation in Germany: an updated analysis
AID  - 10.1101/2023.11.08.23298259
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.11.08.23298259
4099  - http://medrxiv.org/content/early/2023/11/09/2023.11.08.23298259.short
4100  - http://medrxiv.org/content/early/2023/11/09/2023.11.08.23298259.full
AB  - Introduction Advertising of unhealthy foods to children is a key public health concern as exposure to such advertising has been shown to adversely affect children’s food preferences, choices, purchases and intake. The proposed Children’s Food Advertising Act (Kinder-Lebensmittel-Werbegesetz or KLWG) in Germany aims to regulate such marketing by using an adapted version of the World Health Organization Regional Office for Europe Nutrient Profile Model (WHO NPM). Since the first announcement of the proposed new legislation in February 2023, several revisions to the proposed law have been made. In the present study, we evaluate the reach and public health implications of the planned law’s latest draft proposed in June 2023, updating a previously published analysis of the initial proposal.Methods Our analysis is based on a dataset from the open-source online database Open Food Facts, comprising 660 food products randomly selected from the German market. We assigned these products to the 22 food and beverage categories covered the WHO NPM. We then applied the nutrient and ingredient thresholds of the the June 2023 version of the KLWG to this sample to assess the share of products permitted for marketing to children under the proposed legislation.Results Applying the adjustments from the June 2023 KLWG version increased the proportion of products allowed for marketing to children in three product categories, namely plant-based milks (from 70% to 73%), yogurt and cream (from 13% to 73%) and fresh and frozen meat, fish and eggs (from 93% to 100%). Overall, this raised the median share of products across all 22 product categories permitted for marketing to children from 38% to 55%, with an interquartile range of 11%-73%.Conclusion Our previous study found the use of the WHO NPM, as part of the KLWG, to be feasible in the German context and suggested additional threshold adjustments. The latest draft of the KLWG from June 2023 incorporated several of these, substantially increasing the proportion of products allowed for marketing to children. This analysis provides an updated perspective on the evolving debate and its implications for public health.Competing Interest StatementPvP reports receiving research funding from Germany's Federal Ministries of Food and Agriculture (BMEL), Education and Research (BMBF) and the Environment and Consumer Protection (BMUV), as well as travel costs and speaker and manuscript fees from the German and Austrian Nutrition Societies (DGE and OEGE), the German Diabetes Society (DDG) and the German Obesity Society (DAG). OH is an employee of the German Diabetes Society (DDG) and the German Obesity Society (DAG), and has previously been an employee of foodwatch. The staff positions of AL, NH and PvP are funded through research grants from Germany's Federal Ministries of Food and Agriculture (BMEL) and Education and Research (BMBF).Clinical Protocols https://doi.org/10.17605/OSF.IO/BJEVC Funding StatementThis work was conducted without external funding through staff positions at Ludwig-Maximilians-Universitaet Muenchen (LMU Munich), Germany, and the German Obesity Society (DAG), Berlin, Germany.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://doi.org/10.17605/OSF.IO/BJEVC